Literature DB >> 26232660

Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: A review.

Mohammed Afzal Azam1, Janarthanan Thathan2, Selvaraj Jubie2.   

Abstract

GyrB and ParE are type IIA topoisomerases and found in most bacteria. Its function is vital for DNA replication, repair and decatenation. The highly conserved ATP-binding subunits of DNA GyrB and ParE are structurally related and have been recognized as prime candidates for the development of dual-targeting antibacterial agents with broad-spectrum potential. However, no natural product or small molecule inhibitors targeting ATPase catalytic domain of both GyrB and ParE enzymes have succeeded in the clinic. Moreover, no inhibitors of these enzymes with broad-spectrum antibacterial activity against Gram-negative pathogens have been reported. Availability of high resolution crystal structures of GyrB and ParE made it possible for the design of many different classes of inhibitors with dual mechanism of action. Among them benzimidazoles, benzothiazoles, thiazolopyridines, imidiazopyridazoles, pyridines, indazoles, pyrazoles, imidazopyridines, triazolopyridines, pyrrolopyrimidines, pyrimidoindoles as well as related structures are disclosed in literatures. Unfortunately most of these inhibitors are found to be active against Gram-positive pathogens. In the present review we discuss about studies on novel dual targeting ATPase inhibitors.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATPase inhibitors; GyrB; ParE; Pyrrolopyrimidines

Mesh:

Substances:

Year:  2015        PMID: 26232660     DOI: 10.1016/j.bioorg.2015.07.004

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  7 in total

1.  Inhibitors of DNA Gyrase-GyrB Subunit and/or Topoisomerase IV-ParE Subunit May Treat Infectious Diseases Caused by Antibiotic-Resistant Bacteria.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2017-05-26       Impact factor: 4.345

Review 2.  The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics.

Authors:  Michelle F Richter; Paul J Hergenrother
Journal:  Ann N Y Acad Sci       Date:  2018-02-15       Impact factor: 5.691

3.  Thiosemicarbazide Derivatives Decrease the ATPase Activity of Staphylococcus aureus Topoisomerase IV, Inhibit Mycobacterial Growth, and Affect Replication in Mycobacterium smegmatis.

Authors:  Aleksandra Kowalczyk; Agata Paneth; Damian Trojanowski; Piotr Paneth; Jolanta Zakrzewska-Czerwińska; Paweł Stączek
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

4.  Total Synthesis of Kibdelomycin.

Authors:  Chi He; Yu Wang; Cheng Bi; David S Peters; Timothy J Gallagher; Johannes Teske; Jason S Chen; Rachel Corsetti; Anthony D'Onofrio; Kim Lewis; Phil S Baran
Journal:  Angew Chem Int Ed Engl       Date:  2022-07-06       Impact factor: 16.823

5.  Benzohydrazide and Phenylacetamide Scaffolds: New Putative ParE Inhibitors.

Authors:  Vidyasrilekha Yele; Bharat Kumar Reddy Sanapalli; Ashish D Wadhwani; Afzal Azam Mohammed
Journal:  Front Bioeng Biotechnol       Date:  2021-06-17

6.  Rational design of balanced dual-targeting antibiotics with limited resistance.

Authors:  Akos Nyerges; Tihomir Tomašič; Martina Durcik; Tamas Revesz; Petra Szili; Gabor Draskovits; Ferenc Bogar; Žiga Skok; Nace Zidar; Janez Ilaš; Anamarija Zega; Danijel Kikelj; Lejla Daruka; Balint Kintses; Balint Vasarhelyi; Imre Foldesi; Diána Kata; Martin Welin; Raymond Kimbung; Dorota Focht; Lucija Peterlin Mašič; Csaba Pal
Journal:  PLoS Biol       Date:  2020-10-05       Impact factor: 8.029

7.  New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.

Authors:  Martina Durcik; Denise Lovison; Žiga Skok; Cristina Durante Cruz; Päivi Tammela; Tihomir Tomašič; Davide Benedetto Tiz; Gábor Draskovits; Ákos Nyerges; Csaba Pál; Janez Ilaš; Lucija Peterlin Mašič; Danijel Kikelj; Nace Zidar
Journal:  Eur J Med Chem       Date:  2018-05-10       Impact factor: 6.514

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.